title: Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplant patients: a report from the European Group for Blood and Marrow Transplantation (EBMT). Infectious Diseases Working Party of the EBMT.
abstract: The best treatment of CMV gastrointestinal disease has been controversial, with some centers adding intravenous (i.v.) Ig to antiviral chemotherapy. The aim of this retrospective survey was to compare the outcome of antiviral chemotherapy with or without i.v. Ig. A questionnaire was sent to centers belonging to the EBMT. Thirty-three patients with CMV gastrointestinal disease were reported, 22 patients were given antiviral chemotherapy alone and 11 patients a combination of antiviral chemotherapy and i.v. Ig. Eighteen of 33 (55%) patients responded to therapy, 13 of those treated with antiviral chemotherapy alone and five (45%) of those treated with the combination (P = NS). Patients with acute GVHD of grades II-IV had significantly worse outcomes than patients with acute GVHD grades 0-I. In a Cox proportional hazards model corrected for acute GVHD there was no difference in outcome of CMV gastrointestinal disease with or without addition of Ig. Survival at 100 days after diagnosis of CMV gastrointestinal disease was 64%. There was no difference in survival in patients treated with or without i.v. Ig. The results of this retrospective survey indicate that addition of i.v. Ig to antiviral chemotherapy might not improve outcome in patients with biopsy-proven CMV gastrointestinal disease.
authors.forename: P
authors.initials: P
authors.lastname: Ljungman
authors.forename: C
authors.initials: C
authors.lastname: Cordonnier
authors.forename: H
authors.initials: H
authors.lastname: Einsele
authors.forename: C
authors.initials: C
authors.lastname: Bender-Götze
authors.forename: A
authors.initials: A
authors.lastname: Bosi
authors.forename: A
authors.initials: A
authors.lastname: Dekker
authors.forename: R
authors.initials: R
authors.lastname: De la Camara
authors.forename: J
authors.initials: J
authors.lastname: Gmür
authors.forename: A C
authors.initials: AC
authors.lastname: Newland
authors.forename: H G
authors.initials: HG
authors.lastname: Prentice
authors.forename: A J
authors.initials: AJ
authors.lastname: Robinson
authors.forename: M
authors.initials: M
authors.lastname: Rovira
authors.forename: W
authors.initials: W
authors.lastname: Rösler
authors.forename: D
authors.initials: D
authors.lastname: Veil
mesh_terms: D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002648:Child; D003586:Cytomegalovirus Infections / Q000150:complications / Q000628:therapy*; D005260:Female; D005767:Gastrointestinal Diseases / Q000150:complications / Q000628:therapy* / Q000821:virology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011024:Pneumonia, Viral / Q000150:complications / Q000628:therapy; D012189:Retrospective Studies; D011795:Surveys and Questionnaires; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D016756:Immunoglobulins, Intravenous